ArticleBioactive materials2025
Mitochondria-targeted MXene@MnO
Article in Bioactive materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Mitophagy-mediated immune evasion: Shared strategies of pathogens.Redox biology · 2026Review
- Igniting cold tumors: reprogramming the tumor immune microenvironment with dual-payload ADCs in combination with PD-L1&4-1BB bispecific antibodies.Journal for immunotherapy of cancer · 2026Article
- Self-Assembly of Stimuli-Responsive Peptide Enhances Therapeutics by Specifically Disrupting Hepatocellular Carcinoma Lysosomes In Vivo.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Metal-dependent regulated cell death: Molecular architecture and translational frontiers.iMeta · 2026Review
- Polymer Nanoparticle-Based Photodynamic Therapy Combined with Immunotherapy for Solid Tumor Treatment.Current issues in molecular biology · 2026Review
- Cascaded, self-decomposing messenger in MXene@Cu-MOF heterostructures for on-demand infection control and pro-angiogenic wound repair.Materials today. Bio · 2026Article
- Stimuli-responsive nanoplatforms for sonodynamic immunotherapy: opportunities and challenges in cancer treatment.Frontiers in immunology · 2026Review
- Nanoengineered mitochondria for mitochondrial dysfunction and anti-aging interventions.Frontiers in aging · 2025Review
Corrections and comments
- Erratum issued
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mitochondrial DNA (mtDNA) functions as an endogenous danger-associated molecular pattern that broadly activates the cGAS-STING pathway to potentiate antitumor immunotherapy. However, inefficient mtDNA release severely limits its ability to robustly activate downstream immune responses. Recent studies reveal that ferroptosis can trigger mtDNA release from damaged mitochondria into the cytosol, thereby stimulating antitumor immunity. Thus, precisely modulating mitochondria-associated ferroptosis to promote mtDNA-dependent cGAS-STING activation represents a promising strategy for enhancing immunotherapy. Here, we engineered a mitochondria-targeted MXene@MnO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.